Late in 2015, one of the pioneering stem cell and regenerative medicine biotechs, Ocata Therapeutics (fka as ACT or Advanced Cell Technology) was acquired by Astellas Pharma. At the time of purchase, Ocata had a number of areas of focus, but was most closely followed for its development of human embryonic stem cell-based retinal pigmented epithelial …
Brief update from Bob Lanza on Astellas stem cell program Read More »
I asked Ocata CSO, Bob Lanza, for a comment on the big news of the acquisition of the company by Astellas. Here’s what he had to say: “I can say that this is an exciting time for regenerative medicine. The merger should greatly accelerate the pace of discovery, and, I hope, lead to treatments for …
Brief quote from Bob Lanza on Ocata acquisition by Astellas Read More »
Before I did the #icebucketchallenge, I challenged the leader of Advanced Cell Technology (ACT), Dr. Bob Lanza, to do the Ice Bucket Challenge. He did it and leading up to it he provided a quite articulate message for context (see video below). Bob is one very cool guy even without ice water. The purpose of the …
I did a brief email Q&A interview with Dr. Bob Lanza of Advanced Cell Technology (ACT) on their new hES MSCs pre-clinical data for Multiple Sclerosis. I discussed the paper itself in a concise review yesterday here. Thanks to Dr. Lanza for doing the interview. 1. Were you surprised at the fact that the therapeutic …
Interview with Bob Lanza on new ACT MSCs for MS paper Read More »
The recent news of Vertex Pharma buying small stem cell biotech ViaCyte and Doug Melton moving to Vertex brought to mind an old stem cell biotech called Advanced Cell Technology (ACT) and its leader, stem cell biologist Dr. Robert Lanza. Years ago, big pharma firm Astellas bought ACT and Lanza moved to be a leader of regenerative …
What new papers and news in the stem cell sphere caught your eye? Here are some recent items that seem notable to me. Diabetes relief in mice by glucose-sensing insulin-secreting human α-cells. This paper reports cellular reprogramming to insulin-producing cells in mice. They reprogrammed α-cells with Pdx1 and MafA proteins. ‘Mitophagy inhibits amyloid-β and tau pathology and reverses …
Recent stem cell pubs & news: reprogramming, chromatin, single-cell, Astellas, & more Read More »
Who are the top stem cell influencers? Terrapin asked this kind of question to some within our community 4 years ago and came up with a Top 50 list of stem cell influencers, which I like to joke I was “at the top of” because I was #50 and they listed us in reverse chronological order. …
List of Top 50 stem cell influencers on Twitter to follow Read More »
Here is a link to the Ocata website, marking the start of a new era for what was formerly Advanced Cell Technology or ACT. It’s been a big summer for stem cell biotech Advanced Cell Technology (ACT; stock ACTCD) as it continues what I would call a process of reinventing itself. What’s been happening? ACT recently …
ACT reinventing itself with new name Ocata Therapeutics Read More »
This post is a tribute to the late Dr. Yoshiki Sasai (笹井芳樹). If you would like your name added to this tribute please let me know. You are also welcome to add your own tributes in the comments. In an era when the emerging field of regenerative medicine is just beginning to take wing, we …
Stem Cell Community Tribute to Yoshiki Sasai (笹井芳樹) Read More »
A new human therapeutic cloning paper is out today, the third in a matter of months. This one is from the lab group of Dr. Dieter Egli published in Nature demonstrating production of nuclear transfer embryonic stem cells (NT-ESCs) from an adult human somatic donor via somatic cell nuclear transfer (SCNT). This human SCNT paper follows …
Cloning is cloned again: New Nature Paper is 3rd on Human SCNT Read More »